Regentis Biomaterials Ltd.
Records under this name other than the patents Regentis Biomaterials Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 7 patents it holds.
Showing 1 to 6 of 6 · Back to Regentis Biomaterials Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,007,774 | Matrix Composed of a Naturally-Occurring Protein Backbone Cross Linked by a Synthetic Polymer and Methods of Generating and Using Same Term ended Term ended Dec 31, 2025 · High confidence | Term ended | Term ended Dec 31, 2025 | High confidence |
| US 8,858,925 | Pegylated Fibrinogen Precursor Molecule Term ended Ended no later than Jun 28, 2025 · Medium confidence | Term ended | Ended no later than Jun 28, 2025 | Medium confidence |
| US 9,700,600 | Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same Term ended Term ended Jan 5, 2025 · From the USPTO record | Term ended | Term ended Jan 5, 2025 | From the USPTO record |
| US 7,842,667 | Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same Term ended Term ended Dec 15, 2024 · From the USPTO record | Term ended | Term ended Dec 15, 2024 | From the USPTO record |
| US 9,474,830 | Pegylated Fibrinogen Precursor Molecule Lapsed on the fee record Ended Oct 25, 2024 · Medium confidence | Lapsed on the fee record | Ended Oct 25, 2024 | Medium confidence |
| US 5,595,980 | Contraceptive compositions Term ended Term ended no later than Jan 21, 2017 · Low confidence | Term ended | Term ended no later than Jan 21, 2017 | Low confidence |